Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 14
Submit an article Journal homepage
276
Views
20
CrossRef citations to date
0
Altmetric
Review

Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry

Giuseppe Benagiano Professor and Dean University ‘la Sapienza’, Postgraduate School of Gynaecology and Obstetrics, Policlinico Umberto I°, Viale Regina Margherita 245, 00161 Roma, Italy
, MD PhD FACOG(hon) FRCOG(ad eundem) Hon Sen(Szeged),
Carlo Bastianelli Associate Professor University ‘la Sapienza’, Department of Gynaecology and Obstetrics, Policlinico Umberto I°, Viale Regina Margherita 245, 00161 Roma, Italy
, MD PhD &
Manuela Farris Research Associate University ‘la Sapienza’, Department of Gynaecology and Obstetrics, Policlinico Umberto I°, Viale Regina Margherita 245, 00161 Roma, Italy +39 06 490 398; +39 06 4997 2455; [email protected]
, MD PhD
Pages 2487-2496 | Published online: 08 Sep 2008

Bibliography

  • Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 1: use during pregnancy. Expert Opin Pharmacother 2008;9(14):2459-72
  • Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother 2008;9(14):2473-85
  • Beier HM, Spitz IM. Progesterone antagonists in reproductive medicine and oncology. Hum Reprod 1994;9(Suppl 1)
  • Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 2000;65:807-15
  • Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003;68:981-93
  • Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307
  • Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007;13:567-80
  • Klijn JGM, Setyono-Han B, Foekens JA. progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000;65:825-30
  • Bardon S, Vignon F, Chalbos D, Rochefort H. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab 1985;60:692-7
  • Bakker GH, Setyono-Han B, Henkelmann MS, et al. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH-analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 1987;71:1021-7
  • Bardon S, Vignon E, Montcourrier P, Rochefort H. Steroid receptor mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 1987;47:1441-8
  • Kloosterboer JH, Godefrides H, Deckers WGEJ, et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 2000;65:733-40
  • Wiehle RD, Christov K, Mehta R. Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep 2007;18:167-74
  • Jovanovic-Pole A, Li Y, Kim Y, et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;1467:314
  • Schoenlein PV, Hou M, Samaddar JS, et al. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol 2007;31:643-55
  • Romieux G, Maudelonde T, Ulmann A, et al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987;74:455-559
  • Klijn JGM, De Jong FH, Bakker GH, et al. Antiprogestins: a new form of endocrine therapy for breast cancer. Cancer Res 1989;49:2851-6
  • Jonat W. First clinical results of antiprogestational treatment with onapristone. In: Symposium on ‘Antiprogestins, A New Strategy in Endocrine Cancer Therapy’: 21 Annual Meeting of the German Cancer Society; 1994
  • Perrault D, Eisenhauer EA, Pritchard KI, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1996;14:2709-12
  • Robertson JFR, Willsher PC, Winterbottom L, et al. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 1999;35:214-8
  • Rose FV, Barnea ER. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 1996;12:999-1003
  • Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007;13:3370-9
  • Qin TN, Wang LL. Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism (in Chinese). Di Yi Jun Yi Da Xue Xue Bao 2002;22:344-6
  • Liu Y, Wang LL, Deng Y. Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo (in Chinese). Di Yi Jun Yi Da Xue Xue Bao 2003;23:242-4
  • Rocereto TF, Saul HM, Aikins JA Jr, Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 2000;77:429-32
  • Cabeza M, Bratoeff E, Heuze I, et al. Antiandrogenic and apoptotic effects of RU-486 on animal prostate. J Steroid Biochem Mol Biol 2007;104:321-5
  • Honer CH, Kiyean N, Fink C, et al. Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol Pharmacol 2003;63:1012-20
  • World Health Organisation: Comprehensive Cervical Cancer Control: A Guide to Essential Practice. Geneva: World Health Organaisation; 2006
  • Jurado R, López-Flores A, Álvarez-Figueroa A, García-López P. Synergistic effects of mifepristone on the cytotoxicity of cisplatin in cervical carcinoma cell lines and tumors grown in athymic mice. BMC Cancer 2007;7(Suppl 1):A18
  • Koivisto-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet Gynecol 2007;109:512-4
  • Liote F, Lestang P, Pelissier-Langbort C. Effet anti-tumoral du RU 486 sur un leiomyosarcome osseux disseminé. Rev Rhum 1994;17
  • Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod 1994;9(Suppl 1):202-7
  • Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresecatable meningiomas with the anti-progesterone agent mifepristone. J Neurosurg 1991;74:861-4
  • Grunberg SM, Rankin C, Townsend J, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. San Francisco. Am Soc Clin Oncol 2001;20
  • Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727-33
  • Arnett-Mansfield RL, Defazio A, Mote PA, Clarke CL. Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metab 2004;89:1429-42
  • Brenner RM, Slayden OD, Critchley HO. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 2002;124:167-72
  • Slayden OD, Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab 2003;88:946-9
  • Han S, Sidell N. RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metab 2003;88:713-9
  • Jiang J, Wu R, Wang Z, et al. Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 2002;77:995-1000
  • Li A, Felix JC, Minoo P, et al. Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril 2005;84:202-11
  • Schneider CC, Gibb RK, Taylor DD, et al. Inhibition of endometrial cancer cell lines by mifepristone (RU486). J Soc Gynecol Invest 1998;5:334-8
  • Mirkin S, Archer DF. Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone. Contraception 2004;70:327-33
  • Kamradt MC, Mohideen N, Vaughan AT. RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol 2000;77:177-82
  • Navo MA, Smith JA, Anjali-Gaikwad A, et al. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol 2007
  • Spitz IM, Robbins A. Antiprogestins in clinical practice. In: Sitruk-Ware R, Mishell DR, editors, Progestins and antiprogestins in clinical practice. Paris: Marcel Dekker; 1999. p 377-90
  • Halevy A, Samuk I, Halpern Z, et al. Mifepristone (RU486), a pure antiprogesterone drug, in combination with vinblastine for the treatment of progesterone receptor desmoid tumor. Tech Coloproctol 2007
  • Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003;68:981-93
  • Garrel DR, Moussali R, De Oliveira A, et al. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism. J Clin Endocrinol Metab 1995;80:379-85
  • Gaillard RC, Poffet D, Riondel AM, Saurat JH. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 1985;61:1009-11
  • Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007;157:561-9
  • Newfield RS, Kalaitzoglou G, Licholai T, et al. Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers. J Clin Endocrinol Metab 2000;85:14-21
  • Contreras P. Adrenal cancer: tumor regression with ketoconazole or mifepristone (RU 486). In vivo and in vitro evidence supporting tumoral hormone dependency. In: Proceedings of the 69th Annual Endocrine Society Meeting; 1987. p. 23
  • Pearson-Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997;22(Suppl 1):S125-32
  • Belanoff JK, Flores BH, Kalezhan M, et al. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001;21:516-21
  • Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatr 2002;52:386-92
  • Gallagher P, Malik N, Newham J, et al. Anti-glucocorticoid treatments for mood disorders. Cochrane Database Sys Rev 2008;(1)
  • Nihalani ND, Schwartz TL. Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Curr Opin Invest Drugs 2007;8:563-9
  • Bilgin YM, Van Der Wiel HE, Fischer HR, De Herder WW. Treatment of severe psychosis due to ectopic Cushing's syndrome. J Endocrinol Invest 2007;30:776-9
  • Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol Clin 2007;25:611-67
  • Dhikav V, Anand KH. Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486). Med Hypotheses 2007;68:1088-92
  • Belanoff JK, Jurik J, Schatzberg LD, et al. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. Mol Neurosci 2002;19:201-6
  • Pomara N, Doraiswamy PM, Tun H, Ferris S. Mifepristone (RU 486) for Alzheimer's disease. Neurology 2002;58:1436-42
  • Debattista C, Belanoff J. C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease. Curr Alzheimer Res 2005;2:125-9
  • Pomara N, Hernando RT, De La Pena CB, et al. The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease. Neurochem Res 2006;31:585-8
  • Oomen CA, Mayer JL, De Kloet ER, et al. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress. Eur J Neurosci 2007;26:3395-401
  • Mondry A. Antiglucocorticoid RU38486 reduces net protein catabolism in experimental acute renal failure. BMC Nephrol 2005;17:2-13
  • Wang Y, Tsay SY, O'malley BW. An antiprogestin regulable gene switch for induction of gene expression in vivo. Adv Pharmacol 2000;47:343-55
  • Nordstrom JL. The antiprogestin-dependent GeneSwitch® system for regulated gene therapy. Steroids 2003;68:1085-94
  • Sirin O, Park F. Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristone-inducible system. Gene 2003;323:67-77

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.